Home/Pipeline/APVO711

APVO711

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Aptevo Therapeutics

About Aptevo Therapeutics

Aptevo Therapeutics is a Seattle-based biotech focused on developing next-generation, multi-specific antibody therapies for cancer. The company's core strategy is its proprietary protein engineering platform, which enables the rational design of T-cell engagers and co-stimulatory molecules with tunable properties to potentially overcome limitations of current immunotherapies. Its most advanced asset, mipletamig (APVO436), is a CD3xCD123 bispecific in Phase 1/2 development for acute myeloid leukemia (AML). Operating as a lean, publicly-traded entity, Aptevo aims to advance its broad, early-stage pipeline through clinical validation and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Hematologic Cancer Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active